Trials / Completed
CompletedNCT00596271
Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440
Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX® 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 192 (actual)
- Sponsor
- Valneva Austria GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440
Detailed description
This is a randomized, controlled, multi-center, single-blind phase 3 study. The study population consists of male and female healthy subjects, aged at least 18 years. 192 subjects will be enrolled at 2 sites in Europe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IC51 | |
| BIOLOGICAL | HAVRIX | |
| OTHER | Placebo |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2006-07-01
- Completion
- 2008-08-01
- First posted
- 2008-01-16
- Last updated
- 2014-05-13
- Results posted
- 2014-05-13
Source: ClinicalTrials.gov record NCT00596271. Inclusion in this directory is not an endorsement.